← Back to Screener
NextCure, Inc. Common Stock (NXTC)
Price$11.00
Favorite Metrics
Price vs S&P 500 (26W)79.81%
Price vs S&P 500 (4W)2.62%
Market Capitalization$44.83M
All Metrics
Book Value / Share (Quarterly)$9.97
P/TBV (Annual)0.21x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-14.15
Price vs S&P 500 (YTD)-13.92%
Net Profit Margin (TTM)-65.22%
EPS (TTM)$-21.58
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-21.58
EPS (Annual)$-2.00
ROI (Annual)-85.53%
Net Profit Margin (5Y Avg)-825.97%
Cash / Share (Quarterly)$11.93
ROA (Last FY)-69.26%
EBITD / Share (TTM)$-18.90
ROE (5Y Avg)-45.43%
Operating Margin (TTM)-82.06%
Cash Flow / Share (Annual)$-14.15
P/B Ratio1.28x
P/B Ratio (Quarterly)1.42x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)0.69x
ROA (TTM)-109.17%
EPS Incl Extra (Annual)$-2.00
Current Ratio (Annual)4.14x
Quick Ratio (Quarterly)3.96x
3-Month Avg Trading Volume0.04M
52-Week Price Return236.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.54
P/S Ratio (Annual)2.00x
Asset Turnover (Annual)0.07x
52-Week High$15.74
Operating Margin (5Y Avg)-865.37%
EPS Excl Extra (Annual)$-2.00
CapEx CAGR (5Y)-32.45%
Tangible BV CAGR (5Y)60.79%
26-Week Price Return83.80%
Quick Ratio (Annual)3.96x
13-Week Price Return-5.90%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.14x
Enterprise Value$18.844
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-1.30%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-163.54%
Cash / Share (Annual)$11.93
3-Month Return Std Dev64.40%
Net Income / Employee (TTM)$-1
ROE (Last FY)-85.53%
EPS Basic Excl Extra (Annual)$-2.00
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-21.58
ROI (TTM)-152.90%
P/S Ratio (TTM)1.64x
Pretax Margin (5Y Avg)-825.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.03
Price vs S&P 500 (52W)206.80%
Year-to-Date Return-11.28%
5-Day Price Return12.31%
EPS Normalized (Annual)$-2.00
ROA (5Y Avg)-39.88%
Net Profit Margin (Annual)-163.54%
Month-to-Date Return17.88%
Cash Flow / Share (TTM)$-2.22
EBITD / Share (Annual)$-1.90
Operating Margin (Annual)-184.23%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-45.40%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-21.58
P/TBV (Quarterly)0.28x
P/B Ratio (Annual)1.42x
Pretax Margin (TTM)-65.22%
Book Value / Share (Annual)$9.97
Price vs S&P 500 (13W)-6.59%
Beta1.70x
P/FCF (Annual)9.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-152.90%
52-Week Low$3.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NXTCNextCure, Inc. Common Stock | 1.64x | — | — | — | $11.00 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
NextCure is a clinical-stage biopharmaceutical company developing immunomedicines to restore immune function in cancer and immune-related diseases. Its lead candidate, NC410, a LAIR-2 fusion protein, demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, while LNCB74, an antibody-drug conjugate targeting B7-H4, is also in clinical development. The company is seeking strategic partners for additional clinical programs including NC525 and NC318, as well as preclinical candidates in chronic bone diseases and neurological indications.